Definition
Kelactorphan is a synthetic, non‑peptidic inhibitor of several metallopeptidases that degrade endogenous opioid peptides, most notably neutral endopeptidase (NEP), aminopeptidase N (APN) and dipeptidyl peptidase‑IV (DPP‑IV). It is employed primarily as a research tool to study the physiological role of enkephalins and related neuropeptides.
Overview
Kelactorphan was first described in the late 1990s as a high‑affinity, broad‑spectrum “enkephalinase” inhibitor. By blocking the enzymatic breakdown of enkephalins, it raises their extracellular concentrations, thereby enhancing endogenous opioid signaling. In pre‑clinical animal models, administration of kelactorphan produces dose‑dependent antinociceptive (pain‑relieving) effects that are reversible by opioid antagonists such as naloxone, confirming that its actions are mediated through opioid pathways. Despite its potency in experimental settings, kelactorphan has not been developed for clinical use, largely because of pharmacokinetic limitations and the availability of more selective inhibitors for therapeutic purposes.
Etymology / Origin
The name “kelatorphan” appears to be a coined term combining a prefix likely derived from “kela‑,” possibly referencing the research laboratory or a code name, with the suffix “‑orphan,” a common ending in the nomenclature of enzyme inhibitors (e.g., “carboxypeptidase inhibitor”). No authoritative source provides a definitive etymology, and the precise origin of the term remains undocumented in the scientific literature.
Characteristics
| Property | Description |
|---|---|
| Chemical class | Small‑molecule, non‑peptidic metallopeptidase inhibitor |
| Primary targets | Neutral endopeptidase (NEP, EC 3.4.24.11), aminopeptidase N (APN, EC 3.4.11.2), dipeptidyl peptidase‑IV (DPP‑IV, EC 3.4.14.5) |
| Mechanism of action | Binds to the active‑site zinc ion of metallopeptidases, competitively inhibiting substrate access and thereby preventing degradation of enkephalins and related peptides |
| Pharmacodynamics | Increases extracellular concentrations of Met‑enkephalin and Leu‑enkephalin; produces analgesia, anti‑inflammatory effects, and modulation of stress responses in animal studies |
| Pharmacokinetics | Limited oral bioavailability; typically administered intravenously or intracerebroventricularly in experimental protocols |
| Research applications | Used to elucidate the role of endogenous opioids, to validate enkephalinase inhibition as a therapeutic strategy, and as a comparator compound in the development of more selective inhibitors |
| Safety profile | Acute toxicity data are limited; high doses in rodents have shown signs of hypotension and bradycardia, likely due to widespread inhibition of peptidases with physiological functions beyond opioid peptide catabolism |
Related Topics
- Enkephalinase inhibitors – a class of compounds (e.g., thiorphan, racecadotril, RB‑101) that block the enzymatic breakdown of enkephalins; some have progressed to clinical use for analgesia or gastrointestinal disorders.
- Neutral endopeptidase (NEP) – a membrane‑bound zinc metallopeptidase involved in the catabolism of multiple neuropeptides; inhibition of NEP is a therapeutic target in hypertension and pain.
- Endogenous opioid system – the physiological system comprising opioid peptides (enkephalins, endorphins, dynorphins) and their receptors, regulating analgesia, mood, and stress.
- Metallopeptidase inhibition – a broader pharmacological strategy that includes inhibitors of matrix metalloproteinases, angiotensin‑converting enzyme, and others, often exploiting zinc‑binding groups.
Note: The information presented reflects the current consensus in peer‑reviewed biochemical and pharmacological literature. No clinical applications of kelatorphan have been reported to date.